Usted buscó: myelomonocytic (Inglés - Rumano)

chronic myelomonocytic leukaemia (cmml).
leucemia mielomonocitară cronică (lmmc).

chronic myelomonocytic leukaemia(2)(4), pancreatic adenocarcinoma(5)
leucemie mielomonocitară cronică(2)(4), adenocarcinom pancreatic (5)

chronic myelomonocytic leukaemia (cmml) with 10-29% marrow blasts without myeloproliferative disorder,
leucemie mielomonocitară cronică (lmmc) cu 10- 29% blaşti medulari, fără boală mieloproliferativă,

progression of a type of pre-existing cancers with ras mutations (chronic myelomonocytic leukaemia, pancreatic adenocarcinoma)
progresia unor tipuri de cancer cu mutaţie ras pre-existente (leucemie mielomonocitară cronică, adenocarcinom pancreatic)

vidaza is used in patients with an intermediate to high risk of progressing to aml or death; chronic myelomonocytic leukaemia (cmml, a cancer affecting white blood cells called monocytes).
vidaza se utilizează la pacienții cu un risc mediu până la mare de a dezvolta lma sau de deces; leucemie mielomonocitară cronică (lmmc, un tip de cancer care afectează globulele albe numite monocite).

clinical efficacy and safety the efficacy and safety of vidaza were studied in an international, multicenter, controlled, open-label, randomised, parallel-group, phase 3 comparative study (aza ph gl 2003 cl 001) in patients with: intermediate-2 and high-risk mds according to the international prognostic scoring system (ipss), refractory anaemia with excess blasts (raeb), refractory anaemia with excess blasts in transformation (raeb-t) and modified chronic myelomonocytic leukaemia (mcmml) according to the french american british (fab) classification system.
smd cu risc intermediar- 2 şi mare, conform sistemului internaţional de punctaj referitor la prognostic (sipp), anemie refractară cu exces de blaşti (areb), anemie refractară cu exces de blaşti în transformare (areb- t) şi leucemie mielomonocitară cronică modificată (lmmcm), conform sistemului de clasificare francez, american, britanic (fab).